MST1 knockdown inhibits osteoarthritis progression through Parkin-mediated mitophagy and Nrf2/NF-κB signalling...

Area of Science:

• Biomedical Science
• Molecular Biology
• Pathology

Background:

• Osteoarthritis (OA) is a complex degenerative joint disease.
• Apoptosis and mitophagy are key cellular processes implicated in OA pathogenesis.
• MST1, a pro-apoptotic factor, is upregulated in OA and contributes to disease progression.

Purpose of the Study:

• To investigate the therapeutic potential of MST1 inhibition in osteoarthritis.
• To elucidate the underlying molecular mechanisms of MST1's protective effects in OA.

Main Methods:

• Immunofluorescence (IF) for MST1 expression analysis.
• Western Blot, ELISA, and IF to assess protein expression related to inflammation, ECM degradation, apoptosis, and mitophagy.
• MST1 inhibition using siRNA and shRNA in vitro and in vivo.
• Histological staining (Haematoxylin-Eosin, Safranin O-Fast Green, Alcian Blue) for therapeutic evaluation.

Main Results:

• Elevated MST1 expression was observed in osteoarthritis patients.
• MST1 inhibition in vitro reduced inflammation, ECM degradation, and apoptosis, while enhancing mitophagy.
• In vivo studies demonstrated that MST1 inhibition slows OA progression.
• MST1 inhibition suppressed apoptosis, inflammation, and ECM degradation by promoting Parkin-mediated mitophagy and activating the Nrf2-NF-κB axis.

Conclusions:

• MST1 inhibition exhibits a significant protective effect against osteoarthritis.
• MST1 inhibition represents a potential therapeutic strategy for osteoarthritis treatment.
• The therapeutic benefits are mediated through the promotion of mitophagy and modulation of the Nrf2-NF-κB signaling pathway.